L&C Bio Co., Ltd

KOSDAQ 290650.KQ

L&C Bio Co., Ltd EBITDA Margin for the year ending December 31, 2023: 19.46%

L&C Bio Co., Ltd EBITDA Margin is 19.46% for the year ending December 31, 2023, a -28.20% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

L&C Bio Co., Ltd EBITDA Margin for the year ending December 31, 2022 was 27.10%, a -22.97% change year over year.
L&C Bio Co., Ltd EBITDA Margin for the year ending December 31, 2021 was 35.19%, a 30.19% change year over year.
L&C Bio Co., Ltd EBITDA Margin for the year ending December 31, 2020 was 27.03%, a -22.13% change year over year.
L&C Bio Co., Ltd EBITDA Margin for the year ending December 31, 2019 was 34.71%, a 15.36% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

KOSDAQ: 290650.KQ

L&C Bio Co., Ltd

CEO	Mr. Chul Lee Whan
IPO Date	Nov. 1, 2018
Location	South Korea
Headquarters	Suntechcity
Employees	122
Sector	Health Care
Industries Biotechnology Cosmetics Pharmaceuticals Research & Consulting

Description

L&C BIO Co., Ltd. operates as a research and development company in tissue regeneration medicine. It offers human tissue, medical device, and cosmetics products. The company was founded in 2011 and is headquartered in Seongnam, South Korea.

Key trends

Past 5 years